· Trials · Trials Desk
TRIUMPH-OSA and TRIUMPH-4 expand recruitment as the triple agonist posts a 24% mean weight reduction at 48 weeks in mid-stage data.
This brief is part of the Novusyn Research news desk. We track peptide clinical readouts, regulatory actions, and pharma developments in neutral, evidence-led language for scientifically literate readers.
For related context, see the full news desk, clinical trials tracker, regulation tracker, compound directory, and guides library.